We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Mylan Waives U.S. Exclusivity for Possible COVID-19 Drug
Mylan Waives U.S. Exclusivity for Possible COVID-19 Drug
Mylan said it will waive its exclusive U.S. distribution rights for its copycat of AbbVie’s HIV antiviral Kaletra (lopinavir/ritonavir) to allow other suppliers to manufacture the potential COVID-19 treatment.